CompanyDeals

Medisan Pharmaceutical Secures PPAR Agonist Technology from China Pharmaceutical University

Company

Meihua International Medical Expands with New Healthcare Industrial Park in Hainan

CompanyDrug

Ascletis Pharma’s ASC40 Meets Acne Treatment Goals in Phase II Trial

CompanyDrug

BDgene Technology’s BD111 Receives Tacit Approval for HSV-1 Keratitis Trial

CompanyDrug

SanReno Therapeutics Completes Dosing in Kidney Disease Trial for BION-1301

CompanyDrug

Qilu Pharmaceutical Launches First Generic Iressa in the US Market

CompanyDeals

NeuExcell Therapeutics Secures Over $14.5 Million in Pre-Series A+ Funding for Neurological Treatments

CompanyDrug

Transcenta’s Osemitamab Achieves Full Enrollment in Phase II Gastric Cancer Study

CompanyDrug

TYK Medicines’ TY-9591 Gains CDE Green Light for Pivotal Phase II Study in NSCLC with Brain Metastases

Policy / Regulatory

NMPA Transitions Desloratadine, Loratadine, Ambroxol, and Naproxen to OTC Status

CompanyDrug

Skyline Therapeutics Reports Positive Preclinical Results for SKG0106 and SKG0201 Gene Therapies

CompanyDeals

Cellular Biomedicine Group Inc. and Janssen Biotech, Inc. Announce Global Collaboration for CAR-T Therapies